Fluorescent chromophores in anticancer therapy: Mechanisms and advances.

IF 2.4 Q3 Medicine
Mani Rajasekar, Meenambigai Sivakumar
{"title":"Fluorescent chromophores in anticancer therapy: Mechanisms and advances.","authors":"Mani Rajasekar, Meenambigai Sivakumar","doi":"10.1016/j.ctarc.2026.101221","DOIUrl":null,"url":null,"abstract":"<p><p>Fluorescent Chromophore compounds are characterized by their unique light-absorbing properties. They have emerged as promising candidates in anticancer research due to their ability to interact with cellular components through photodynamic, photothermal, and other therapeutic mechanisms. Recent advancements in synthetic chromophore compounds, such as Coumarin, Fluorescein, Quinoline, and Rhodamine have demonstrated significant anticancer activity by inducing apoptosis, inhibiting cell proliferation, and disrupting tumor vasculature. The integration of chromophores with nanotechnology and targeted drug delivery systems has enhanced their therapeutic efficacy and selectivity, minimizing side effects. Moreover, their role in photoactivation has opened avenues for non-invasive cancer treatments. Despite these advances, challenges such as drug resistance, limited bioavailability, and potential toxicity need to be addressed. This review summarizes recent developments in fluorescent chromophore-based anticancer therapies, highlighting their mechanisms and potential in combination strategies, while addressing future directions for overcoming current limitations in clinical applications.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101221"},"PeriodicalIF":2.4000,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ctarc.2026.101221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Fluorescent Chromophore compounds are characterized by their unique light-absorbing properties. They have emerged as promising candidates in anticancer research due to their ability to interact with cellular components through photodynamic, photothermal, and other therapeutic mechanisms. Recent advancements in synthetic chromophore compounds, such as Coumarin, Fluorescein, Quinoline, and Rhodamine have demonstrated significant anticancer activity by inducing apoptosis, inhibiting cell proliferation, and disrupting tumor vasculature. The integration of chromophores with nanotechnology and targeted drug delivery systems has enhanced their therapeutic efficacy and selectivity, minimizing side effects. Moreover, their role in photoactivation has opened avenues for non-invasive cancer treatments. Despite these advances, challenges such as drug resistance, limited bioavailability, and potential toxicity need to be addressed. This review summarizes recent developments in fluorescent chromophore-based anticancer therapies, highlighting their mechanisms and potential in combination strategies, while addressing future directions for overcoming current limitations in clinical applications.

荧光发色团在抗癌治疗中的作用:机制和进展。
荧光发色团化合物具有独特的吸光特性。由于它们能够通过光动力、光热和其他治疗机制与细胞成分相互作用,它们已成为抗癌研究中有希望的候选者。最近合成的发色团化合物,如香豆素、荧光素、喹啉和罗丹明,通过诱导细胞凋亡、抑制细胞增殖和破坏肿瘤血管系统,显示出显著的抗癌活性。发色团与纳米技术和靶向药物传递系统的整合提高了它们的治疗效果和选择性,最大限度地减少了副作用。此外,它们在光激活中的作用为非侵入性癌症治疗开辟了道路。尽管取得了这些进展,但仍需要解决诸如耐药性、有限的生物利用度和潜在毒性等挑战。本文综述了基于荧光发色团的抗癌疗法的最新进展,强调了它们的机制和联合策略的潜力,同时指出了克服目前临床应用局限性的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书